205309-81-5
205309-81-5 结构式
基本信息
中文别名
化合物 T11055 英文别名
DL-TBOABYOBCYXURWDEDS-IUCAKERBSA-N
D,L-THREO-B-BENZYLOXYASPARTATE
DL-threo-β-Benzyloxyasparticacid
DL-THREO-BETA-BENZYLOXYASPARTIC ACID
D-Aspartic acid, 3-(phenylmethoxy)-, (3R)-rel-
物理化学性质
沸点421.7±45.0 °C(Predicted)
密度1.392±0.06 g/cm3(Predicted)
储存条件Desiccate at -20°C
溶解度<23.92mg/ml in DMSO;insoluble in H2O
酸度系数(pKa)2.07±0.27(Predicted)
形态固体
颜色白色
DL-TBOA价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-107522 | DL-TBOA DL-TBOA | 205309-81-5 | 5mg | 2900元 |
| 2025/02/08 | HY-107522 | DL-TBOA DL-TBOA | 205309-81-5 | 10mM * 1mLin DMSO | 3190元 |
| 2025/02/08 | HY-107522 | DL-TBOA DL-TBOA | 205309-81-5 | 10mg | 4500元 |
常见问题列表
生物活性
DL-TBOA 是一种有效的不可运输的兴奋性氨基酸转运蛋白抑制剂，对兴奋性氨基酸转运蛋白 1 (EAAT1)，EAAT2 和 EAAT3 的 IC50 值分别为 70 μM，6 μM 和 6 μM。DL-TBOA 抑制表达人 EAAT1 和 EAAT2 的 COS-1 细胞摄取 [14C]谷氨酸，Ki 值分别为 42 μM 和 5.7 μM。DL-TBOA 以竞争性方式阻断 EAAT4 和 EAAT5，Ki 值分别为 4.4 μM 和 3.2 μM。靶点
IC50: 70 μM (EAAT1), 6 μM (EAAT2) and 6 μM (EAAT3); Ki: 42 μM (human EAAT1), 5.7 μM (human EAAT2), 4.4 μM (EAAT4) and 3.2 μM (EAAT5)
体外研究
DL-TBOA (70-350 μM; 48 hours; HCT116 and LoVo cell lines) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability.
DL-TBOA (350 μM; 24 hours; HCT116 and LoVo cell lines) treatment decreases p53 induction by SN38 and oxaliplatin.
Cell Viability Assay
| Cell Line: | HCT116 and LoVo cell lines |
| Concentration: | 70 μM, 350 μM |
| Incubation Time: | 48 hours |
| Result: | Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death. |
Cell Viability Assay
| Cell Line: | HCT116 and LoVo cell lines |
| Concentration: | 350 μM |
| Incubation Time: | 24 hours |
| Result: | p53 induction by SN38 and oxaliplatin was decreased. |
体内研究
DL-TBOA (10 nmol; i.c.v.) to morphine-dependent rats significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion.
| Animal Model: | Male Sprague-Dawley rats (180-250 g) |
| Dosage: | 1 nmol, 3 nmol, 10 nmol |
| Administration: | Intracerebroventricularly injection (i.c.v.) |
| Result: | Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg)-precipitated morphine withdrawal. |